{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T19:09:21Z","timestamp":1772564961210,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13304-021-01167-4","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T13:12:09Z","timestamp":1632489129000},"page":"675-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-1839","authenticated-orcid":false,"given":"Takamasa","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kaneoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuyuki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Seita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"crossref","unstructured":"Kamarajah SK, Phillips AW, Ferri L, Hofstetter WL, Markar SR. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study. Br J Surg. 2021","DOI":"10.1093\/bjs\/znaa121"},{"key":"1167_CR2","doi-asserted-by":"crossref","unstructured":"Sato Y, Motoyama S, Wada Y, Wakita A, Kawakita Y, Nagaki Y, et al. Neoadjuvant Chemoradiotherapy Followed by Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma Patients with Clinical Stage III and with Supraclavicular Lymph Node Metastasis. Cancers. 2021;13(5).","DOI":"10.3390\/cancers13050983"},{"issue":"1","key":"1167_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19(1):68\u201374","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"1167_CR4","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12274","volume":"104","author":"H Hara","year":"2013","unstructured":"Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S et al (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104(11):1455\u20131460","journal-title":"Cancer Sci"},{"issue":"9","key":"1167_CR5","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1245\/s10434-014-3684-8","volume":"21","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M et al (2014) Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Ann Surg Oncol 21(9):2838\u20132844","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1167_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000348383","volume":"84","author":"H Iwase","year":"2013","unstructured":"Iwase H, Shimada M, Tsuzuki T, Hirashima N, Okeya M, Hibino Y et al (2013) Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial. Oncology 84(6):342\u2013349","journal-title":"Oncology"},{"key":"1167_CR7","doi-asserted-by":"crossref","unstructured":"Wang W, Xing D, Song Y, Liu F. Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: a systematic review and meta-analysis protocol. Medicine (Baltimore). 2018;97(12):e0164.","DOI":"10.1097\/MD.0000000000010164"},{"issue":"10","key":"1167_CR8","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/cas.12764","volume":"106","author":"M Tahara","year":"2015","unstructured":"Tahara M, Fuse N, Mizusawa J, Sato A, Nihei K, Kanato K et al (2015) Phase I\/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II\/III esophageal carcinoma (JCOG 0604). Cancer Sci 106(10):1414\u20131420","journal-title":"Cancer Sci"},{"issue":"1060","key":"1167_CR9","doi-asserted-by":"publisher","first-page":"20150476","DOI":"10.1259\/bjr.20150476","volume":"89","author":"M Li","year":"2016","unstructured":"Li M, Fu C, Zhang W, Huang W, Wang Z, Zhou T et al (2016) Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol 89(1060):20150476","journal-title":"Br J Radiol"},{"issue":"3","key":"1167_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.21037\/jtd.2016.02.70","volume":"8","author":"Y Ji","year":"2016","unstructured":"Ji Y, Qiu G, Sheng L, Sun X, Zheng Y, Chen M et al (2016) A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. J Thorac Dis 8(3):451\u2013458","journal-title":"J Thorac Dis"},{"key":"1167_CR11","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. [Internet]. Somerset: Wiley; 2011 [cited 2021 Apr 6]. http:\/\/public.ebookcentral.proquest.com\/choice\/publicfullrecord.aspx?p=4043906"},{"key":"1167_CR12","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990. 2009 45(2):228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"1167_CR13","first-page":"107","volume":"1","author":"Japanese Society for Esophageal Diseases","year":"2004","unstructured":"Japanese Society for Esophageal Diseases (2004) Guidelines for clinical and pathologic studies on carcinoma of the esophagus ninth edition: part II. Esophagus 1:107\u2013125","journal-title":"Esophagus"},{"issue":"1","key":"1167_CR14","first-page":"37","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society (2017) Japanese Classification of Esophageal Cancer, 11th Edition: part II and III. Esophagus Off J Jpn Esophageal Soc 14(1):37\u201365","journal-title":"Esophagus Off J Jpn Esophageal Soc"},{"issue":"2","key":"1167_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205\u2013213","journal-title":"Ann Surg"},{"issue":"3","key":"1167_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000495700","volume":"42","author":"S Sun","year":"2019","unstructured":"Sun S, Yu H, Wang H, Zhang H, Wu X, Wang J et al (2019) Phase II study of S-1 plus cisplatin as first-line therapy in patients with metastatic esophageal carcinoma. Oncol Res Treat 42(3):115\u2013122","journal-title":"Oncol Res Treat"},{"issue":"3","key":"1167_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jjco\/hyp153","volume":"40","author":"M Fujii","year":"2010","unstructured":"Fujii M, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J et al (2010) Phase I\/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced\/recurrent head and neck cancer. Jpn J Clin Oncol 40(3):214\u2013221","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"1167_CR18","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1245\/s10434-018-6554-y","volume":"25","author":"E Toxopeus","year":"2018","unstructured":"Toxopeus E, van der Schaaf M, van Lanschot J, Lagergren J, Lagergren P, van der Gaast A et al (2018) Outcome of patients treated within and outside a randomized clinical trial on neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: extrapolation of a randomized clinical trial (CROSS). Ann Surg Oncol 25(8):2441\u20132448","journal-title":"Ann Surg Oncol"},{"key":"1167_CR19","doi-asserted-by":"crossref","unstructured":"Hayata K, Ojima T, Nakamori M, Nakamura M, Katsuda M, Kitadani J, et al. Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for resectable advanced esophageal cancer. ANTICANCER Res. 2018;7.","DOI":"10.21873\/anticanres.12852"},{"issue":"11","key":"1167_CR20","doi-asserted-by":"publisher","first-page":"e1650","DOI":"10.1634\/theoncologist.2020-0546","volume":"25","author":"M Kanda","year":"2020","unstructured":"Kanda M, Koike M, Iwata N, Shimizu D, Tanaka C, Hattori N et al (2020) An Open-Label Single-arm phase II study of treatment with neoadjuvant S-1 plus cisplatin for clinical stage III squamous cell carcinoma of the esophagus. Oncologist 25(11):e1650\u2013e1654","journal-title":"Oncologist"},{"issue":"3","key":"1167_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cgh.2018.05.044","volume":"17","author":"F Islami","year":"2019","unstructured":"Islami F, DeSantis CE, Jemal A (2019) Incidence trends of esophageal and gastric cancer subtypes by race, ethnicity, and age in the United States, 1997\u20132014. Clin Gastroenterol Hepatol 17(3):429\u2013439","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"1167_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V et al (2010) Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol Off J Am Soc Clin Oncol 28(9):1547\u20131553","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"33","key":"1167_CR23","doi-asserted-by":"publisher","first-page":"35107","DOI":"10.18632\/oncotarget.5959","volume":"6","author":"YH Li","year":"2015","unstructured":"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP et al (2015) S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget 6(33):35107\u201335115","journal-title":"Oncotarget"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-021-01167-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-021-01167-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-021-01167-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T09:17:21Z","timestamp":1649582241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-021-01167-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1007\/s13304-021-01167-4","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"15 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TT, YK, AM, YT, and KS declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving Human Participants and\/or Animals"}},{"value":"Informed consent was obtained from all individual participants included in this study.Supplementary file1 (TIFF 17225\u00a0KB).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}